- Coordinator
- Universita Di Pisa, Italy
- Runs
- 1 March 2023 to 28 February 2027
- Status
- Running
- EU funding
- €3.6m
- Total cost
- €3.6m
- Partners
- 7 organisations in 6 countries
- Type
- European Innovation Council
- Grant agreement
- 101099310
What the project is doing
In the project's own words, from its summary on CORDIS.
Insufficient sleep is an under-reported epidemic and sleep disturbances are common early signs of neurodegeneration. Clinical research is currently challenging the assumption that human sleep is a one-fits-all phenomenon: breaking new grounds into sleep research is needed. NAP makes real the study of individual sleep pathophysiology through a new science-to-technology paradigm merging in vitro modelling, allometric scaling, signal processing and micromanufacturing.
NAP targets five breakthroughs: 1) the development of the first model enabling the accurate study of individual sleep, 2) the realization of the cyborganoid, i.e., the next generation of biohybrid model of the human brain, 3) the setup of an experimental procedure to mimic sleep in vitro accounting for a person’s lifestyle, metabolism and genetic makeup, 4) the exploitation of allometry to obtain meaningful information from in vitro to humans and 5) the delivery of the first tool for Parkinson’s Disease (PD) early diagnosis.
As a Proof of Principle, NAP will identify the effects of sleep deprivation and detect sleep-related signs of PD in a personalised perspective. In the long-term, NAP will move Europe to lead sleep research and innovation through its envisioned technology: a predictive medicine twin-on-a-chip allowing the public at large to be routinely screened for i) checking their sleep health, ii) being warned about the consequences of sleep loss, iii) predating PD and other neuropathies characterized by sleep anomalies.
This will be of benefit for science, society and economy. NAP Proof of Principle will deliver the first tool for accurately extrapolating biological parameters from in vitro to humans. The identification of individual sleep needs will allow the targeted detection of people suffering from sleep disorders, scaling back healthcare costs. Sleep-related neurodegeneration biomarkers will have tremendous implications in pharmacological research and enterprise and in the healthcare sector
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Di Pisa | Pisa | Italy | Coordinator |
| Atlas Neuroengineering Bvba | Leuven | Belgium | Participant |
| Albert-Ludwigs-Universitaet Freiburg | Freiburg | Germany | Participant |
| Sleepacta S.r.l. | Pisa | Italy | Participant |
| Organotherapeutics GmbH | Esch-Sur-Alzette | Luxembourg | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Participant |
| Slovenska Technicka Univerzita V Bratislave | Bratislava | Slovakia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI